8-K ·Filed Sep 14, 2026

CABA

Cabaletta Bio, Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed18d 4h ago SEC0001759138-26-000041
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The massive near-expiration exercise wave suggests the stock traded above the $2.50 warrant price throughout Q3 2026, which is consistent with a $463M market cap. With the warrant overhang now largely extinguished (only ~1.8M warrants unexercised), the primary equity overhang is removed. Monitor upcoming Q3 2026 financials for the cash balance impact and any forward guidance on pipeline spending.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
CABA ▼ -15.46% at T+5d
NEUTRAL call ✗ call lost -15.46% · α vs SPY -15.57% · entry $2.91 → $2.46
Next anchor: T+20d in 10d
Latest observation: T+9 -29.49% FF3 residual α
Entry anchored
Sep 14, 07:19 AM ET
via 1-min bar
T+1d
-10.82%
call -10.82% · α -10.37%
$2.60
settled 17d ago
T+5d
-15.46%
call -15.46% · α -15.57%
$2.46
settled 11d ago
T+20d
—
call — · α —
—
in 10d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2026, and that 97% (46.0M of 53.1M) were exercised in the three months before expiration, generating $115M in aggregate gross proceeds in Q3 2026 and ~$128.2M total since issuance. The filing is a routine update on warrant exercise activity and contains no new operational or pipeline developments.

Key Facts

  • 53,090,190 common stock warrants were issued in June 2025 with a $2.50 exercise price and an expiration date of September 12, 2026.
  • 5,275,100 warrants were exercised from issuance through June 30, 2026, generating ~$13.2M in gross proceeds.
  • 46,011,900 warrants were exercised from July 1, 2026 through the expiration date, generating ~$115.0M in aggregate gross proceeds.
  • Total aggregate gross proceeds from all warrant exercises: approximately $128.2 million.

Financial Impact

Cabaletta received approximately $128.2 million in gross proceeds from warrant exercises, including ~$115.0M in the last ~2.5 months before expiration.

cash_and_cash_equivalents

Risk Factors

  • Dilution from the remaining ~1.8M warrants that were not exercised is minimal.
  • The ~$128M cash infusion could pressure management to show progress on pipeline catalysts to justify the stock's valuation.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759138-26-000041
Document: 0001759138-26-000041-index-headers.html0001759138-26-000041
Document: 0001759138-26-000041-index.html0001759138-26-000041
Document: 0001759138-26-000041.txt0001759138-26-000041
17 reports for CABA
Performance horizon
75% Hit rate 6 of 8 directional calls best @ T+60▲ +31.59%May 4, 2026
Filters
Rows
Reports for CABA — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
8-K
NEUTRAL ★ 4/10
$2.91 $2.46▼ −15.46%▼ −15.57%$1.91 (−34.36%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 5/10
$2.89 $3.10▲ +7.27%▲ +8.46%$1.91 (−33.91%)
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.91 (−29.52%)
Aug 13, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$2.71 $3.19▲ +17.71%▲ +19.68%$1.91 (−29.52%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 5/10
$3.01 $2.84▼ −5.65%▼ −6.32%$1.91 (−36.54%)
Jun 3, 2026
17w ago
8-K
BULLISH ★ 7/10
$3.58 $3.04▼ −15.08%▼ −11.26%$1.91 (−46.65%)
Jun 1, 2026
17w ago
DEFA14A
NEUTRAL ★ 3/10
$3.67 $3.25▼ −11.44%▼ −8.69%$1.91 (−47.96%)
May 14, 2026
20w ago
8-K
BEARISH ★ 6/10
$3.61 $3.69▼ −2.22%▼ −2.93%$1.91 (+47.09%)
May 14, 2026
20w ago
Press Release
NEUTRAL ★ 4/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.91 (−47.09%)
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$3.61 $3.69▲ +2.22%▲ +2.93%$1.91 (−47.09%)
Showing 10 of 17

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access